FTC Reviews Curium-Lantheus Merger After Second Request
The $8 billion acquisition is now delayed as the FTC extends the regulatory waiting period for both companies.
Updated on Oct. 23, 2026 in Healthcare
Live Poll
Do you believe federal regulators should strictly scrutinize large corporate mergers to ensure market competition?
The Federal Trade Commission has issued Second Requests to Curium US Holdings LLC and Lantheus Holdings, extending the regulatory review period for their proposed $8 billion acquisition. The deal, which aims to make Lantheus a subsidiary of Curium, now faces an extended Hart-Scott-Rodino waiting period.
Why it matters
The FTC review indicates closer scrutiny of the transaction, which typically delays final closing timelines and increases compliance costs for the involved parties. Operators in heavily regulated sectors should note that such intervention resets the clock on deal finalization.
The deal is valued at $8 billion, with a baseline offer of $102.50 per share plus a $12 contingent value right. The Hart-Scott-Rodino waiting period remains in effect for at least 30 days following the companies' substantial compliance with the FTC request.
The players
Federal Trade Commission
The U.S. agency responsible for enforcing antitrust laws and conducting merger reviews to protect market competition.
Curium US Holdings LLC
A company involved in the healthcare sector currently seeking to expand its operations through the acquisition of Lantheus.
Lantheus Holdings
A healthcare firm and the target entity in the proposed $8 billion acquisition by Curium.
Coco Merger Sub Inc.
A subsidiary of Curium established as a vehicle to execute the merger into Lantheus.
The details
Under the merger agreement, Curium subsidiary Coco Merger Sub Inc. will merge into Lantheus, leaving the latter as a wholly owned subsidiary. The FTC's Second Request process requires both companies to provide additional data and documentation to verify that the acquisition does not violate competition laws. This action pauses the statutory waiting period, which only resumes 30 days after the parties have substantially complied with the government's investigative demands.
Timeline
Aug 3, 2026: The companies signed the original merger agreement.
Oct 21, 2026: The Federal Trade Commission issued Second Requests to the firms.
First half 2027: The companies currently target this period for deal closure.
Market Landscape
This development follows the standard investigative protocol established by the Hart-Scott-Rodino Antitrust Improvements Act for large-scale corporate mergers. The move aligns with recent trends in federal oversight where regulators increase scrutiny of consolidation in specialized industry sectors.
Operators planning for potential industry consolidation should factor in extended regulatory timelines that can stretch beyond initial projections. Management teams must prepare for intensive document production and potential operational restructuring demands during the extended FTC review process.
The takeaway
The FTC intervention highlights the necessity of building regulatory buffer time into long-term strategic acquisition plans. For firms involved in major deal-making, monitor progress on data production as the primary indicator for the resumption of the 30-day clock.
Further reading
For broader trends in industry regulation and corporate consolidation, see Healthcare.
Source note: This article includes information reported by TokenPost.
Live Poll
Do you believe federal regulators should strictly scrutinize large corporate mergers to ensure market competition?
